🏛️ Verified NIH Record • Updated 2026-07-27
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (NCT04058756)
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Who can join: Review the eligibility criteria below.
Location: Columbia University Medical Center — New York, New York
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (48 Sites)
Showing the first 25 of 48 sites.
- Columbia University Medical Center — New York, New York
- Providence Portland Medical Center — Portland, Oregon
- MD Anderson Cancer Center Uni of Te — Houston, Texas
- Novartis Investigative Site — Leuven,
- Novartis Investigative Site — Liège,
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Guangzhou, Guangdong
- Novartis Investigative Site — Guangzhou,
- Novartis Investigative Site — Brno,
- Novartis Investigative Site — Lille,
- Novartis Investigative Site — Lyon,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Villejuif,
- Novartis Investigative Site — Jena, Thuringia
- Novartis Investigative Site — Essen,
- Novartis Investigative Site — Heidelberg,
- Novartis Investigative Site — Ulm,
- Novartis Investigative Site — Hong Kong, Hong Kong
- Novartis Investigative Site — High West,
- Novartis Investigative Site — Hong Kong,
- Novartis Investigative Site — Debrecen, Hajdu Bihar Megye
- Novartis Investigative Site — Budapest,
- Novartis Investigative Site — Milan, MI
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.